Cargando…
Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
BACKGROUND: Factor XIII (FXIII) is the final enzyme of the coagulation cascade. While the other enzymatic coagulation factors are proteases, FXIII belongs to the transglutaminase family. FXIIIa covalently crosslinks the fibrin clot and represents a promising target for drug development to facilitate...
Autores principales: | Pasternack, Ralf, Büchold, Christian, Jähnig, Robert, Pelzer, Christiane, Sommer, Michael, Heil, Andreas, Florian, Peter, Nowak, Götz, Gerlach, Uwe, Hils, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973046/ https://www.ncbi.nlm.nih.gov/pubmed/31578814 http://dx.doi.org/10.1111/jth.14646 |
Ejemplares similares
-
Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
por: Büchold, Christian, et al.
Publicado: (2022) -
Structure‐Based Design of FXIIIa‐Blockers: Addressing a Transient Hydrophobic Pocket in the Active Site of FXIIIa
por: Stieler, Martin, et al.
Publicado: (2020) -
Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
por: Scheres, Luuk J.J., et al.
Publicado: (2021) -
Guidance on the critical shortage of sodium citrate coagulation tubes for hemostasis testing
por: Gosselin, Robert C., et al.
Publicado: (2021) -
Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)